TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:TLRY - US88688T1007 - Common Stock
11.23 CAD
+1.26 (+12.64%)
Overall TLRY gets a fundamental rating of 2 out of 10. We evaluated TLRY against 31 industry peers in the Pharmaceuticals industry. TLRY may be in some trouble as it scores bad on both profitability and health. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLRY has reported negative net income.
In the past year TLRY has reported a negative cash flow from operations.
In the past 5 years TLRY always reported negative net income.
TLRY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -103.13%, TLRY is not doing good in the industry: 83.87% of the companies in the same industry are doing better.
The Return On Equity of TLRY (-139.41%) is worse than 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 28.69%, TLRY perfoms like the industry average, outperforming 45.16% of the companies in the same industry.
In the last couple of years the Gross Margin of TLRY has grown nicely.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLRY has more shares outstanding
TLRY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
2.2 Solvency
TLRY has an Altman-Z score of -1.69. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TLRY (-1.69) is worse than 67.74% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that TLRY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.18, TLRY is in line with its industry, outperforming 54.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.69 |
ROIC/WACCN/A
WACC7.98%
2.3 Liquidity
TLRY has a Current Ratio of 2.62. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.62, TLRY is doing good in the industry, outperforming 61.29% of the companies in the same industry.
TLRY has a Quick Ratio of 1.56. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY has a Quick ratio of 1.56. This is in the better half of the industry: TLRY outperforms 67.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The earnings per share for TLRY have decreased strongly by -6498.00% in the last year.
Looking at the last year, TLRY shows a small growth in Revenue. The Revenue has grown by 2.31% in the last year.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
The Earnings Per Share is expected to grow by 14.94% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.31% on average over the next years.
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TLRY's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.39 |
4.3 Compensation for Growth
TLRY's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.34%
EPS Next 3Y25.98%
5. Dividend
5.1 Amount
TLRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TLRY (12/9/2025, 7:00:00 PM)
11.23
+1.26 (+12.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.33%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap1.30B
Revenue(TTM)830.77M
Net Income(TTM)-2.15B
Analysts71.25
Price Target23.95 (113.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2631.48%
Min EPS beat(2)-5362.97%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-1385.84%
Min EPS beat(4)-5362.97%
Max EPS beat(4)100%
EPS beat(8)2
Avg EPS beat(8)-708.23%
EPS beat(12)2
Avg EPS beat(12)-746.7%
EPS beat(16)4
Avg EPS beat(16)-606.4%
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.23%
Max Revenue beat(2)0.41%
Revenue beat(4)1
Avg Revenue beat(4)-6.19%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)0.41%
Revenue beat(8)1
Avg Revenue beat(8)-5.71%
Revenue beat(12)2
Avg Revenue beat(12)-3.59%
Revenue beat(16)2
Avg Revenue beat(16)-3.93%
PT rev (1m)805.82%
PT rev (3m)1665.52%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-788.89%
EPS NY rev (1m)-19.05%
EPS NY rev (3m)54.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.13 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.61 | ||
| P/tB | 1.23 | ||
| EV/EBITDA | 22.39 |
EPS(TTM)-18.27
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS9.92
BVpS18.39
TBVpS9.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.5 | ||
| Cap/Depr | 30.45% | ||
| Cap/Sales | 4.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | -1.69 |
F-Score3
WACC7.98%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
EBIT growth 1Y28.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.61%
EBIT Next 3Y29.12%
EBIT Next 5Y17.36%
FCF growth 1Y-688.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.17%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY.CA FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.CA.
What is the valuation status of TILRAY BRANDS INC (TLRY.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY.CA). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY.CA) stock?
TILRAY BRANDS INC (TLRY.CA) has a profitability rating of 1 / 10.
How financially healthy is TILRAY BRANDS INC?
The financial health rating of TILRAY BRANDS INC (TLRY.CA) is 3 / 10.